Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T20:58:36.467Z.
Calculation as of: 2026-10-06T20:58:36.467Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e88a9ce363f502b6754b19b8a4115a17c58c771a6bc05fe10e5aff55a47e2c9d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Sintx Technologies, Inc.
Market Cap
$13.86M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Sintx Technologies, Inc. (SINT) | $13.86M | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $13.75M | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.05M | N/A |
| IN8bio, Inc. (INAB)vs › | $13.33M | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.30M | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $14.46M | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.20M | N/A |
| Passage Bio, Inc. (PASG)vs › | $13.11M | N/A |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $14.73M | N/A |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.94M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
